“Covid-19 Vaccine” Science-Research, January 2022, Week 4 — summary from ClinicalTrials.gov, Europe PMC and DOAJ

ClinicalTrials.gov — summary generated by Brevi Assistant

This research study is to determine SARS-CoV-2 S healthy protein specific CD8 T cells in the blood of COVID-19 immunized participants. As both vaccinations are mRNA based inscribing S healthy protein of SARS-CoV-2 and need 2 doses, the CD8 T cell response is expected to be similar. We will determine basic wellness factors utilizing blood samples. By assessing the frequency, differentiation, and expansion of these SARS-CoV-2 S protein specific CD8 T cells, we intend to drop light into the CD8 T cell response to COVID-19 vaccine and its modification with age. This is a Phase II, potential, randomized, observer-blinded, multi-center research, to evaluate the safety and security, tolerability, and immunogenicity of a booster vaccination with AZD1222, mRNA-1273, or MVC-COV1901 vaccine. Around 960 participants aged 18 ~< 80 years, that received homologous 2 doses of vaccines 150 ~365 days back, will be enrolled and split right into 3 teams. Each team will consist of 320 qualified subjects, and for each group the randomization will be stratified according to examine site and age to four treatments. Consequently, within a group, for either age stratum, there will go to the very least 30 participants for each treatment. Cancer patients go to enhanced threat from COVID-19 infection death as a result of underlying malignancy, treatment-related immunosuppression, or boosted variety of comorbidities. To assess the safety and security and reactogenicity of a booster dosage of mRNA-1273 vaccine carried out to patients that have formerly obtained an mRNA or alternative vaccine regimen in patients that have a hematological malignancy and are immunosuppressed because of their illness and/or treatment, or obtaining a PD-1/ PDL-1 inhibitor for therapy of a strong growth for patients who are vaccine-naive. Individuals with recognized history of SARS-CoV-2 infection or within 2 weeks of recognized exposure to a person with recognized SARS CoV2 infection COVD-19 are left out. For the vaccine naive mates we plan to sign up 20 individuals with strong tumor malignancies that have launched PD1/PDL1 prevention treatment as component of criterion of treatment and are deemed to have a steady program without the demand for any kind of immunosuppressive treatment or corticosteroids and 60 individuals with leukemia, lymphoma, numerous myeloma and patients post-allogeneic stem cell transplant. Safety concerns of COVID-19 ChAdOx1 nCoV-19 vaccine have caused a recommendation of heterologous increase with mRNA vaccine in numerous countries. In real life, the ChAdOx1 nCoV-19 vaccine appeared to be less efficient than the BNT162b2 and mRNA1273 vaccine in avoiding SARS-COV-2 infection. The Centers for Disease Control of the United States has supported 3rd booster dosage of mRNA vaccine for people in jeopardy of COVID-19 and those who operate in high-risk setups, including medical care workers. Israel expanded its 3rd COVID-19 vaccine increase to those aged over 12 years old.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

  • https://clinicaltrials.gov/ct2/show/NCT04852289 — A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans.
  • https://clinicaltrials.gov/ct2/show/NCT05197153 — A Phase II, Prospective, Randomized, Observer-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Heterologous Booster Dose With AZD1222, mRNA-1273, or MVC-COV1901 COVID-19 Vaccine in Adults.
  • https://clinicaltrials.gov/ct2/show/NCT04847050 — A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1 PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine.
  • https://clinicaltrials.gov/ct2/show/NCT05132855 — Safety, Reactogenicity, and Immunogenicity of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine: a Single-blind and Randomized Study.

Europe PMC — summary generated by Brevi Assistant

Background: Background incidence rates are critical in pharmacovigilance to assist in identification of vaccine security signals. The mean rates of myocarditis and/or pericarditis increased with age as much as 79 years; males had higher rates than women: from 12–59 years for myocarditis and 12 years and older for pericarditis. INTRO: As the protection from the COVID-19 vaccinations diminishes over time, wellness authorities are currently taking into consideration exactly how to keep immunity using vaccine booster dosages. In a recent survey, we explored COVID-19 booster vaccine determination among Danes, a population with a high acceptance of the first round of COVID-19 vaccination. BACKGROUND: We aimed to assess the efficacy of 3 COVID-19 vaccines in a population of health treatment employees at a tertiary cancer center in Amman, Jordan. We utilized Cox regression analyses to compare the dangers of SARS-CoV-2 infection amongst the different vaccine recipient groups and found a dramatically greater infection threat in BBIBP-CorV and ChAdOx1 receivers contrasted to BNT162b2 receivers P =. Multisystem inflammatory disorder in children is one of the most extreme deadly clinical entity associated with pediatric SARS-CoV-2 infection. The major result was the coverage rate of post-vaccine hyper-inflammatory disorder per 1000000 COVID-19 mRNA vaccine doses in 12–17-year-old youngsters. We utilized a noninvasive electrochemical quantitative assay for IgG Abs to SARS-CoV-2 S1 Ag in saliva to explore the kinetics of Abdominal muscle response in a community-based population that had received either the Pfizer or Moderna mRNA-based vaccine. In all people, salivary SARS-CoV-2 S1 IgG Ab levels increased dramatically in the 2-wk duration after their second vaccination, with peak Abdominal muscle levels seen at 10–20 d after vaccination. Background: Limited research has checked out mobile phone-based systems for survey employment, particularly throughout the COVID-19 pandemic in Brazil. From a list of the adult population reluctant for the second dosage of the COVID-19 vaccine, we sent a mobile phone-based advertisement inviting the individuals to answer the survey for one week.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

DOAJ — summary generated by Brevi Assistant

Patients with diabetic issues are a lot more at risk to severe acute respiratory syndrome-associated coronavirus -2 infection, but vaccine hesitancy is a problem in this population. We explored the frequency of SARS-CoV-2 vaccine hesitancy among diabetes patients in China through a cross-sectional study from April and August 2021 utilizing a survey administered to patients at two health centers connected with Changzhi Medical College. Objectives The objective of this study was to identify predictors of COVID-19 vaccine objective among Bangladeshi grownups. Conversation Findings recommend that age, perceived COVID-19 risk, and non-pharmaceutical COVID-19 treatments may anticipate COVID-19 vaccination intent among Bangladeshi adults. Vaccination is the most effective way to control the COVID-19 pandemic, yet vaccination hesitancy threatens this effort worldwide. These outcomes add to the understanding of the function of problematic social media usage in COVID-19 vaccine hesitancy, i. E., It is not the amount of social media sites utilize per se that matters. Although COVID-19 vaccination strategies acknowledge a demand for equity, differences in two-dose vaccine initiation have been observed in the United States. If difference patterns are emerging in COVID-19 vaccination completion, we aim to examine. Them A 16-year-old Thai woman developed right facial palsy, a lower motor nerve cell lesion, and pins and needles 3 h after receiving the first dosage of the BNT162b2 mRNA vaccine. The cerebrospinal fluid account on day 7 after the start of symptoms was typical. History: The objective of today’s work was to assess the reactogenicity and immunogenicity of heterologous COVID-19 vaccination routines in scientific trials and observational studies. Also, this research study supports the application of heterologous regimens against COVID-19 which might supply more opportunities to accelerate the global vaccination project and optimize the capacity to regulate the pandemic.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

Brief Info about Brevi Assistant

The Brevi assistant is a novel way to automatically summarize, assemble, and consolidate multiple text documents, research papers, articles, publications, reports, reviews, feedback, etc., into one compact abstractive form.

At Brevi Assistant, we integrated the most popular open-source databases to empower Researchers, Teachers, and Students to find relevant Contents/Abstracts and to always be up to date about their fields of interest.

Also, users can automate the topics and sources of interest to receive weekly or monthly summaries.




Brevi assistant is the world’s first AI technology able to summarize various document types about the same topic with complete accuracy.

Love podcasts or audiobooks? Learn on the go with our new app.

Recommended from Medium

UK’s Delta Experience Forshadows the US

Why Some People Get Sicker Than Others

Your COVID-19 Response Affects Us All

Social Distancing Is Not Enough

Pest Alert №13 — Dollar Spot Development (isn’t happening) During Dry Chicago Conditions

COVID-19 Vaccine and Me

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Brevi Assistant

Brevi Assistant

Brevi assistant is the world’s first AI technology able to summarize various document types about the same topic with complete accuracy.

More from Medium

We are living in the quantum era’s infancy.

Polymers in Paradise

A colour photograph of a sandy beach looking out to sea at the approach of sunset. In the foreground the beach is littered with a significant amount of plastic waste of varying size, shape and colour.

Neptune’s Illusions